Inhibikase Therapeutics (IKT) Proxy Filing summary

Executive summary

• The annual meeting will be held virtually on June 27, 2025, with shareholders able to attend, vote, and ask questions online.

• Shareholders of record as of May 1, 2025, are eligible to vote on key proposals, including director elections, auditor ratification, and an equity plan amendment.

• Proxy materials and the 2024 Annual Report are available online, with options for electronic or mail voting.

Voting matters and shareholder proposals

• Election of two Class II directors, Amit Munshi and David Canner, Ph.D., to serve until 2028.

• Ratification of CohnReznick LLP as independent auditor for fiscal year 2025.

• Approval of an amendment to the 2020 Equity Incentive Plan to add an automatic “evergreen” provision and extend the plan to 2035.

• Board recommends voting FOR all proposals.

• Shareholder proposals for the 2026 meeting must be submitted by January 12, 2026.

Board of directors and corporate governance

• Board consists of eight members divided into three staggered classes, with only one class elected each year.

• Majority of directors are independent under Nasdaq and SEC rules; only the CEO is not independent.

• Board committees include audit, compensation, and corporate governance/nominating, all composed of independent directors.

• Chairperson and CEO roles are separated to reinforce board independence.

• Board and committees met regularly in 2024, with high attendance.